1 / 10

regory S. Brinton; Sayed S E H Saif; M. Yasser S. Saif; Ahmed T.S. Saif

regory S. Brinton; Sayed S E H Saif; M. Yasser S. Saif; Ahmed T.S. Saif . Bevacizumab ( Avastin ): 2 year results in choroidal neovascularization (CNV) secondary to pathologic myopia (PM). No Financial Interest. M. Yasser S. Saif ,MD* Ahmed T.S. Saif, MD** Gregory S. Brinton, MD***

noreen
Download Presentation

regory S. Brinton; Sayed S E H Saif; M. Yasser S. Saif; Ahmed T.S. Saif

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. regory S. Brinton; Sayed S E H Saif; M. Yasser S. Saif; Ahmed T.S. Saif Bevacizumab (Avastin): 2 year results in choroidal neovascularization (CNV) secondary to pathologic myopia (PM). No Financial Interest

  2. M. Yasser S. Saif ,MD* Ahmed T.S. Saif, MD** Gregory S. Brinton, MD*** Sayed S E H Saif, MD**** *Assistant Prof of ophthalmology Beni sueif university ** lecturer of ophthalmology Fayoum university ***Prof of ophthalmology Utah university ****Prof of ophthalmology Cairo university

  3. PURPOSE: To evaluate the safety and efficacy of intravitrealbevacizumab in the treatment of choroidal neovascularization (CNV) secondary to pathologic myopia (PM). • DESIGN: Prospective, consecutive, nonrandomized, interventional case series.

  4. PARTICIPANTS: Thirty four eyes of 34 patients with CNV secondary to PM. • METHODS: Consecutive patients with subfoveal or juxtafoveal CNV secondary to PM were recruited prospectively to receive an intravitreal injection of bevacizumab. Additional injections were performed in eyes with persistent CNV leakage after 2-6 month durations. • Patients were followed up for 24 months, and BCVA, changes in FFA and OCT results were assessed.

  5. RESULTS: • The mean spherical equivalent refractive error of the 34 eyes was -10.56+/-3.49 D (range, -6.0D to -19.0D). • follow-up period : 24 months. • BCVA • improved in 24 eyes(70.6%) • the same in 6 eyes (17.6%) • decreased in 4(11.8%) eyes.

  6. Case received 3 injectionsin 2 years and the CNV is still progressive

  7. 2007 Feb 2008 BCVA improved 3 lines from base line Dec 2008 2009

  8. Pre injection 18 month (6 injections • The OCT results also showed significant reduction in thickness after treatment. • No systemic complications were noted after intravitreal injections. • One eye (2.9%) had an endophthalmitis and resolved on medical treatment.

  9. Thirty eyes (88.2%) received multiple injections (2-6 injections) • The injection interval varies between 2-13 months

  10. CONCLUSIONS: • The 24-month outcomes suggest intravitrealbevacizumab to be a promising treatment method for CNV secondary to PM, resulting in both visual and anatomic improvements.

More Related